Press Release Oct 23 2025

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials".

View Attachment